What's Happening?
Qlaris Bio, a clinical-stage biotechnology company focused on developing therapies for glaucoma, has appointed Fred Guerard, Pharm.D., as its new President and CEO. Effective March 1, 2026, Guerard will also join the company's Board of Directors. He brings
over two decades of global leadership experience in ophthalmology and biotechnology, having previously served as CEO of Opthea and Graybug Vision. Guerard succeeds Thurein Htoo, who will remain with the company until April 1, 2026, to ensure a smooth transition. Under Guerard's leadership, Qlaris Bio aims to advance its lead candidate, QLS-111, into Phase 3 clinical development.
Why It's Important?
The appointment of Fred Guerard as CEO marks a pivotal moment for Qlaris Bio as it prepares to advance its innovative glaucoma treatment, QLS-111, into late-stage clinical trials. Guerard's extensive experience in ophthalmology and biotechnology is expected to drive the company's strategic growth and commercialization efforts. This leadership change is crucial for Qlaris Bio as it seeks to strengthen its position in the competitive biotechnology industry and address unmet needs in ophthalmology. The successful development and commercialization of QLS-111 could have significant implications for patients with glaucoma, offering a novel treatment option that targets intraocular pressure.
